Research report · October 2026

Clinical trials in Belgium 2026: who runs them, where, and on what

Q: How many clinical trials start in Belgium in 2026?

AcademicLabs found 398 clinical trials with Belgian involvement and a registered start date in 2026, as of 8 October 2026. 191 of them (48%) run only in Belgium; the other 197 are international trials with Belgian sites. Registries keep adding trials after they start, so the count for late 2026 will still grow.

Q: Which Belgian cities host the most new clinical trials?

Brussels has a site in 172 of the 398 trials, Leuven in 160 and Ghent in 104, followed by Antwerp (79) and Liège (57). By region, 280 trials have a site in Flanders, 172 in the Brussels-Capital Region and 94 in Wallonia. A multi-site trial counts in every city where it runs.

Q: Who sponsors clinical trials in Belgium?

Universities and hospitals lead 201 of the 398 trials (51%) and industry leads 187 (47%). 174 trials have a Belgian sponsor; the most active are VUB (Vrije Universiteit Brussel) (26), UCLouvain (26) and UZ Leuven (23). The most active companies are Boehringer Ingelheim (16), Eli Lilly (16), Bristol-Myers Squibb (8).

Q: Which diseases do the 2026 Belgian trials study?

Oncology is the largest area with 81 trials (20%), followed by neurology (45) and cardiovascular disease (42). 54% of all trials have no drug-development phase: they test medical devices, surgery, diagnostics, digital tools and care pathways rather than a new medicine.

Q: How many trials run only in Belgium?

191 trials (48%) list Belgium as their only country, and almost all of them are led by Belgian universities and hospitals. 87% of industry-led trials are international.

Q: Which countries share the most clinical trials with Belgium?

Of the 197 international trials, 134 (68%) also run in the United States, 123 in Spain, 122 in France and 113 in Germany.

Q: Are there obesity drug trials in Belgium in 2026?

Yes. 13 trials target obesity or excess weight, 11 of them run by industry, including studies by Novo Nordisk, Eli Lilly and Roche, some in children and adolescents.

Q: Which researchers lead clinical trials in Belgium in 2026?

85 of the 398 trials name an investigator with a Belgian affiliation in the registry record, 90 researchers in total. The most active are Copine Sylvie (4), Eva Swinnen (3), Bart Roelands (3), Laurent Simar (3). Industry-sponsored trials rarely name investigators in the registry, so the list mostly reflects academic and hospital-led studies.

Q: How was this analysis made?

AcademicLabs AI read each registry record on its own, with no web search and no facts from model memory, and classified it by disease area, intervention, development stage, sponsor type, Belgian sites and Belgian sponsorship. Counting and every figure were done in code. The trials are registered plans: most are recruiting or not yet open, and none of the figures describe results.

Q: Can I reuse these figures?

Yes. The data and figures are licensed CC BY 4.0: free to reuse with credit “Source: AcademicLabs”, with a link to https://academiclabs.com/research-reports/belgium-clinical-trials-2026.

By Arne Smolders, Founder & CEO, AcademicLabs · Published 9 October 2026 · Data as of 8 October 2026

An example report built with AcademicLabs. Get one for your country, disease or technology →

191 of the 398 trials run only in Belgium. Belgian universities and hospitals lead as many trials as industry, Brussels, Leuven and Ghent host the most studies, and 54% test something other than a new drug.

398trials with Belgian involvement starting in 2026

191run only in Belgium

174with a Belgian sponsor

40Belgian cities with a trial site

Lead sponsor type

Academic & hospital	201	51%
Industry	187	47%
Public & non-profit	9	2%
Other / unclear	1	0%

Key figures

398

clinical trials with Belgian involvement started or are scheduled to start in 2026.

48%

run only in Belgium (191 trials). The rest are international.

174

have a Belgian sponsor, led by VUB (Vrije Universiteit Brussel), UCLouvain and UZ Leuven.

51%

are led by universities and hospitals (201), against 187 led by industry.

172

have a site in Brussels, the most of any city. Leuven follows with 160, Ghent with 104.

70%

have a site in Flanders (280). Brussels: 172. Wallonia: 94.

oncology trials make it the largest disease area (20%), ahead of neurology (45).

68%

of the 197 international trials also run in the United States, the most common partner country.

01 · WHERE

Brussels, Leuven and Ghent carry most of the load

Trials with at least one listed site in each city. A multi-site trial counts once in every city where it runs.

Trials per Belgian city

City	Trials	Share of all trials
Brussels	172	43%
Leuven	160	40%
Ghent	104	26%
Antwerp	79	20%
Liège	57	14%
Roeselare	30	8%
Hasselt	26	7%
Bruges	23	6%
Charleroi	19	5%
Genk	18	5%
Namur	16	4%
Aalst	16	4%
Yvoir (Mont-Godinne)	15	4%
Kortrijk	12	3%
Bonheiden	11	3%
Ottignies-Louvain-la-Neuve	10	3%
Mechelen	9	2%
La Louvière	7	2%
Sint-Niklaas	5	1%
Ostend	4	1%
Mons	4	1%
Ieper	3	1%
Dendermonde	2	1%
Tournai	2	1%
Geel	2	1%
Brasschaat	2	1%
Jolimont	2	1%
Ninove	1	0%
Arlon	1	0%
Libramont	1	0%
Verviers	1	0%
Melle	1	0%
Eeklo	1	0%
Lokeren	1	0%
Tongeren	1	0%
Lier	1	0%
Herentals	1	0%
Steenokkerzeel (Melsbroek)	1	0%
Tienen	1	0%
Overpelt	1	0%

Trials per region

Region	Trials with a site there
Flanders	280
Brussels-Capital Region	172
Wallonia	94

02 · WHEN

A steady flow of new studies, month after month

Trials by registered start month. Starts after 8 October 2026 are planned dates, and registries keep adding trials after they begin, so the last months will still grow.

New trials by start month, 2026

281 trials started in the first half of the year. March was the busiest month with 57.

Month	Trials
January	48
February	45
March	57
April	48
May	47
June	36
July	37
August	25
September	30
October	19
November	3
December	3

03 · WHAT

Cancer leads, but half the trials test no drug at all

Oncology is the largest disease area. 54% of the trials have no drug-development phase: they test devices, surgery, diagnostics, apps and care pathways.

Disease area, split by who leads the trial

Disease area	Trials	Academic & hospital	Industry	Public, non-profit or other
Oncology	81	26	51	4
Neurology	45	26	16	3
Cardiovascular	42	22	19	1
Musculoskeletal & rehab	28	27	1	0
Endocrinology or metabolism	27	8	19	0
Gastroenterology or hepatology	24	10	14	0
Multiple areas	19	12	7	0
Respiratory	16	10	6	0
Immunology or rheumatology	16	4	12	0
Rare or genetic disease	15	2	13	0
Hematology	13	4	7	2
Other	13	12	1	0
Infectious disease	12	7	5	0
Psychiatry	9	9	0	0
Healthy volunteers	9	5	4	0
Ophthalmology	7	3	4	0
Kidney & urology	6	3	3	0
Dental & oral	6	4	2	0
Women's health	5	4	1	0
Dermatology	5	3	2	0

Development phase

Phase	Trials
Phase 1	30
Phase 1/2	10
Phase 2	39
Phase 2/3	6
Phase 3	83
Phase 4	14
No phase (non-drug)	216

What is being tested

Intervention	Trials
Small-molecule drug	65
Medical device	57
Biologic or antibody	55
Other	52
Behavioral or digital intervention	45
Diagnostic or imaging intervention	42
Combination	35
Surgery or procedure	26
Supportive care	14
Radiation therapy	3
Vaccine	3
Cell therapy	1

04 · WHO

Belgian universities and hospitals lead as many trials as industry

Lead sponsors of the 2026 trials. Academic and hospital sponsors lead 51% of all trials; most of them are Belgian institutions running studies at home.

Most active lead sponsors

Lead sponsor	Trials	Type	Belgian
VUB (Vrije Universiteit Brussel)	26	Academic & hospital	Yes
UCLouvain	26	Academic & hospital	Yes
UZ Leuven	23	Academic & hospital	Yes
Boehringer Ingelheim	16	Industry	No
Ghent University	16	Academic & hospital	Yes
Eli Lilly	16	Industry	No
KU Leuven	13	Academic & hospital	Yes
Institut Jules Bordet	11	Academic & hospital	Yes
Bristol-Myers Squibb	8	Industry	No
ULiège	8	Academic & hospital	Yes
Johnson & Johnson	8	Industry	No
Pfizer	7	Industry	No
UZA (Antwerp University Hospital)	6	Academic & hospital	Yes
ZOL Genk (Hospital East-Limburg)	6	Academic & hospital	Yes
Bayer	6	Industry	No
Incyte	6	Industry	No
AstraZeneca	6	Industry	No
MSD	6	Industry	No
Novo Nordisk	5	Industry	No
Roche	5	Industry	No
Sanofi	5	Industry	No
AZ Maria Middelares	4	Academic & hospital	Yes
University of Antwerp	4	Academic & hospital	Yes
Jessa Hospital	4	Academic & hospital	Yes
CSL Behring	3	Industry	No

Belgian-led trials

174 of 398 trials (44%) have a Belgian sponsor. 165 of these run only in Belgium. By contrast, 87% of industry-led trials are international studies with Belgian sites.

05 · WORLD

Half run only in Belgium; the other half connect Belgium to the world

Trials that run only in Belgium are mostly academic studies. 87% of industry-led trials are international, most often sharing sites with the United States and Belgium's European neighbours.

Belgium only or international?

Scope	Trials	Share
Belgium only	191	48%
International	197	49%
Belgian link unclear	10	3%

Countries most often sharing a trial with Belgium

Country	International trials	Share
United States	134	68%
Spain	123	62%
France	122	62%
Germany	113	57%
Italy	109	55%
United Kingdom	95	48%
Netherlands	89	45%
Australia	80	41%
Canada	75	38%
Japan	69	35%
Poland	68	35%
China	52	26%
Argentina	50	25%
South Korea	48	24%
Brazil	48	24%
Denmark	44	22%
Austria	44	22%
Czechia	38	19%
Taiwan	37	19%
Portugal	32	16%

06 · STORIES

Six stories in the data

Examples of what new clinical research in Belgium looks like this year. All are planned or ongoing; none has reported results yet.

The obesity-drug race reaches Belgian clinics

13 trials target obesity or excess weight, 11 of them run by industry. Novo Nordisk, Eli Lilly and Roche test next-generation weight-loss drugs here, including in children and adolescents.

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) (NCT07817875)A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight (NCT07253285)

Radioactive tracers to treat and to see

At Institut Jules Bordet, doctors measure how much radiation prostate tumours absorb during lutetium-177 therapy. In Leuven, a first-in-human study tests a PET tracer that could make Huntington’s disease visible in the brain.

LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy. (NCT07370597)iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009 (NCT06634628)

An Alzheimer’s blood test at the GP

UZ Leuven studies whether blood-based Alzheimer’s biomarkers change how general practitioners diagnose and refer patients with memory complaints, and whether they predict cognitive decline.

Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level. (NCT07666113)

Antwerp’s tropical institute tests how long protection lasts

The Institute of Tropical Medicine runs a phase 3 rabies-booster study across four Belgian cities and follows people for two years after an mpox (MVA-BN) booster.

Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming. (NCT07455318)Prospective Follow-up After MVA-BN Booster Vaccination (NCT07342829)

Robots in the operating theatre and the training lab

AZ Maria Middelares in Ghent tests single-port robotic hernia repair. Orsi Academy in Melle compares a hydrogel model with cadaver training for robot-assisted prostate surgery.

Robotic Single Port Combined Umbilical and Inguinal Hernia Repair (NCT07755696)Comparing Two Training Methods for Learning Robot-Assisted Radical Prostatectomy (NCT07669974)

AI and apps enter the trial

In Charleroi an AI system flags lymphoma patients at risk of skipping their oral therapy. At VUB a self-management app is tested against low-back pain in healthcare workers.

AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients. (NCT07546188)Effectiveness of the SelfBack-App in Preventing and Treating Low Back Pain Versus no Intervention: a Non-randomized Clinical Trial (NCT07785804)

Built with AcademicLabs

Want a report like this for your field?

This report is an example of what AcademicLabs builds. Our AI reads every record and stays grounded in the source: no web searches, no facts from model memory, and every figure linked to its record. We make the same for any country, disease, target, technology or topic.

1
Build them yourselfSearch and triangulate all eight types of intelligence with AcademicLabs AI. We show you how.
2
Have them built for youIn-depth, comprehensive reports from €1,000 to €10,000 depending on scope, with optional monthly updates.
3
Stay ahead every monthA monthly briefing on what is new for your topic: startups, competitor moves, trials, results, patents, deals, publications, projects, news and experts.

07 · ALL TRIALS

All 398 trials

Every trial in this report, with its AcademicLabs profile and its registry record.

Start	Trial	Registry	Lead sponsor	Phase	Disease area	Belgian sites
2026-01-01	Assessment of the Effect of Hypoglossal Nerve Stimulation Therapy on Upper Airway Collapsibility During Drug-induced Sleep Endoscopy	NCT07337239	UZA (Antwerp University Hospital)	No phase (non-drug)	Respiratory	Antwerp
2026-01-01	Combined Psma-Pet/Ct and Mri Staging in Intermediate and High-Risk Patients Prostata-Cancer (Combine-P)	NCT07455097	Heinrich-Heine University, Duesseldorf	No phase (non-drug)	Oncology	Leuven
2026-01-01	Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt	NCT07359547	UZ Leuven	No phase (non-drug)	Ophthalmology	Leuven
2026-01-01	Sleep-MOMagement: Improving Postpartum Sleep in First-time Mothers Through Tailored Behavioral Approaches.	NCT07345065	De deyne Manon	No phase (non-drug)	Psychiatry	Leuven, Brussels
2026-01-01	Evaluating the Added Benefit of Osteopathic Care to a Flexi-FODMAP Diet in Fibromyalgia Patients With Irritable Bowel Syndrome	NCT07176078	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Multiple areas	Brussels
2026-01-02	A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion	NCT07063745	Bristol-Myers Squibb	Phase 2/3	Oncology	Brussels, Antwerp, Liège, Roeselare, Yvoir (Mont-Godinne)
2026-01-04	Evaluating the Impact of Cryo-analgesia on Recovery After Double Lung Transplantation	NCT06959056	University Hospital, Gasthuisberg	No phase (non-drug)	Respiratory	Leuven
2026-01-05	Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder	NCT07224581	GRIN Therapeutics	Phase 3	Rare or genetic disease	Brussels
2026-01-05	Pilot Study on Follow-Up of (Acutely) Suicidal Individuals From the Flemish Suicide Helpline	NCT07343258	Ghent University	No phase (non-drug)	Psychiatry	Ghent
2026-01-06	Effect of IMT in Patients After Acute Exacerbations of COPD	NCT07213128	KU Leuven	No phase (non-drug)	Respiratory	Leuven, Brussels, Ghent, Liège
2026-01-07	Airway Microbiome of Patients With Protracted Bacterial Bronchitis	NCT07255430	UZA (Antwerp University Hospital)	No phase (non-drug)	Respiratory	Antwerp
2026-01-07	Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)	NCT07179380	Insmed Inc	Phase 3	Multiple areas	Leuven, Brussels
2026-01-08	SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study	NCT07116668	SafeHeal	No phase (non-drug)	Oncology	Leuven, Antwerp
2026-01-08	Assessment of Nutrient Absorption in Enterally Fed Post-intensive Care Unit Patients Using Bomb Calorimetry: do the Calories Stick	NCT06923813	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Endocrinology or metabolism	Brussels
2026-01-08	A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants	NCT06904261	Amicus Therapeutics Inc	Phase 3	Rare or genetic disease	Leuven
2026-01-08	A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies	NCT07195916	Incyte	Phase 1	Multiple areas	Leuven, Brussels, Antwerp, Ghent
2026-01-08	A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight	NCT07253285	Novo Nordisk	Phase 3	Endocrinology or metabolism	Brussels, Antwerp
2026-01-12	Factors Determining the Rate of Adoption of Pharmaceutical Recommendations by Patients in Primary Care Following a Medication Review by a Pharmacist	NCT07606716	UCLouvain	No phase (non-drug)	Other	Brussels
2026-01-12	Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation in Emergency Departments	NCT07588490	UCLouvain	No phase (non-drug)	Musculoskeletal & rehab	Brussels
2026-01-12	Efficacy and Safety of Micra AV2 Transcatheter Pacing System	NCT07356505	UZ Leuven	No phase (non-drug)	Cardiovascular	Leuven
2026-01-12	A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults	NCT07222137	Eli Lilly	Phase 3	Endocrinology or metabolism	Leuven, Brussels, Antwerp, Namur
2026-01-13	Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer	NCT07245745	UCLouvain	No phase (non-drug)	Oncology	Brussels, Ottignies-Louvain-la-Neuve
2026-01-14	A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)	NCT07298330	Mirum Pharmaceuticals Inc	Phase 3	Gastroenterology or hepatology	Brussels, Antwerp, Liège
2026-01-14	Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis	NCT07325292	Sanofi	Phase 3	Neurology	Brussels, Ghent, Bruges, Kortrijk, Overpelt
2026-01-15	Prospective Follow-up After MVA-BN Booster Vaccination	NCT07342829	Institute of Tropical Medicine	No phase (non-drug)	Infectious disease	Antwerp
2026-01-16	Vorasidenib Maintenance for IDH Mutant Astrocytoma	NCT06809322	European Organisation for Research and Treatment of Cancer	Phase 3	Oncology	Leuven, Brussels, Ghent
2026-01-16	Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations	NCT07195695	Boehringer Ingelheim	Phase 3	Oncology	Leuven, Antwerp, Liège
2026-01-19	A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)	NCT07216703	MSD	Phase 3	Oncology	Leuven, Brussels, Antwerp, Ghent, Liège, Charleroi
2026-01-20	Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management.	NCT07451483	Institut Jules Bordet	No phase (non-drug)	Oncology	Brussels
2026-01-20	Study the Anti-inflammatory Effect of Tranexamic Acid When Used in Anterior Cruciate Ligament Reconstruction.	NCT07332910	Centre Hospitalier Interregional Edith Cavell	Phase 4	Musculoskeletal & rehab	Brussels
2026-01-20	A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies	NCT07308132	Johnson & Johnson	Phase 1	Oncology	Antwerp, Liège
2026-01-20	EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors	NCT07262619	Eikon Therapeutics Inc	Phase 1/2	Oncology	Brussels
2026-01-20	A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)	NCT07359846	Flagship Pioneering	Phase 3	Respiratory	Mechelen
2026-01-21	Mitochondrial Function in Peripheral Blood Mononuclear Cells, Muscle, and Skin of Long COVID Patients	NCT07134673	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Infectious disease	Brussels
2026-01-22	Clinical Safety and Effectiveness of the Straumann Dynamic Navigation System Falcon	NCT07518615	Institut Straumann AG	No phase (non-drug)	Dental & oral	Ghent
2026-01-22	A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease	NCT07184944	Sanofi	Phase 3	Gastroenterology or hepatology	Yvoir (Mont-Godinne)
2026-01-22	Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis	NCT07332091	CSL Behring	Phase 2	Rare or genetic disease	Brussels, Antwerp, Ghent, Liège, Namur, Yvoir (Mont-Godinne)
2026-01-22	A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)	NCT07159841	Crinetics Pharmaceuticals Inc	Phase 2/3	Endocrinology or metabolism	Leuven, Brussels, Antwerp, Ghent
2026-01-24	Objective Measurement of the Mechanical Pain Threshold With an Algometer for Predicting Intraoperative Opioid Consumption in Patients Who Will be Operate by Thoracotomy and Sternotomy in Cardiac Surgery	NCT07513974	ULB	No phase (non-drug)	Cardiovascular	Brussels
2026-01-25	Neoadjuvant Darovasertib in Primary Uveal Melanoma	NCT07015190	IDEAYA Biosciences Inc	Phase 3	Oncology	Leuven, Brussels
2026-01-26	The Effect of Remifentanil on the Objectively Measured Pressure Pain Threshold	NCT07568405	ULB	No phase (non-drug)	Other	Brussels
2026-01-27	Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease	NCT06909045	University of Amsterdam	No phase (non-drug)	Neurology	Leuven
2026-01-27	The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension	NCT07359599	ZOL Genk (Hospital East-Limburg)	Phase 4	Cardiovascular	Leuven, Brussels, Genk, Kortrijk, Yvoir (Mont-Godinne), Charleroi, Aalst
2026-01-29	Feasibility of Upper Airway Stimulation in OSA	NCT07396649	Notos Medical Limited	No phase (non-drug)	Respiratory	Antwerp
2026-01-29	A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice	NCT07344779	Bayer	No phase (non-drug)	Oncology	–
2026-01-30	The Effect of Corticosteroids on Quality of Life Following Total Hip Arthroplasty: HIPSTER Study	NCT07378215	ZOL Genk (Hospital East-Limburg)	Phase 4	Musculoskeletal & rehab	Genk
2026-01-30	Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer	NCT07288177	Genmab AS	Phase 2	Oncology	Leuven, Roeselare, La Louvière, Jolimont
2026-01-31	Preventive Effect of a Dietary Supplement With Two Probiotic Limosilactobacillus Reuteri Strains on Excessive Crying and Colic in Healthy Newborns.	NCT07347743	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Gastroenterology or hepatology	Brussels
2026-02-01	Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)	NCT07234838	Jonathan Krygier	No phase (non-drug)	Dermatology	Brussels
2026-02-01	Prophylactic Intervention for Dysgeusia in Head and Neck Cancer Patients Following Radio(Chemo)Therapy	NCT07431346	Institut Jules Bordet	No phase (non-drug)	Oncology	Brussels
2026-02-01	Assessment of Platelet-derived GARP in Atherosclerotic Disease	NCT07364058	UCLouvain	No phase (non-drug)	Cardiovascular	Brussels
2026-02-01	Assessment of GARP Expression in Acute and Chronic Coronary Syndrome	NCT07384910	UCLouvain	No phase (non-drug)	Cardiovascular	Brussels
2026-02-01	LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.	NCT07370597	Institut Jules Bordet	No phase (non-drug)	Oncology	Brussels
2026-02-01	The Added Value of Transcranial Direct Current Stimulation (tDCS) During Exercise for People With Chronic Widespread Pain	NCT07212829	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Immunology or rheumatology	Brussels
2026-02-01	Untreated Parkinson's Disease Work-up Assessing Resident Microbiota and Duodenal Barrier Function	NCT07418658	UZ Leuven	No phase (non-drug)	Neurology	Leuven
2026-02-01	The Influence of Chemotherapy on Position Sense	NCT07367711	KU Leuven	No phase (non-drug)	Oncology	Leuven
2026-02-01	LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer	NCT06831955	UZ Leuven	Phase 2	Oncology	Leuven, Brussels, Antwerp, Ghent, Liège, Hasselt, Kortrijk, Namur
2026-02-01	Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS	NCT07322003	Prilenia Therapeutics BV	Phase 3	Neurology	Leuven
2026-02-02	Sex-difference in Response to Resistance Exercise and Training	NCT07692815	UCLouvain	No phase (non-drug)	Healthy volunteers	Ottignies-Louvain-la-Neuve
2026-02-02	Exploration of the Effect of a Wheat Polar Lipid Complex on Vaginal Dryness in Healthy Postmenopausal Women	NCT07386249	Air Liquide SA	No phase (non-drug)	Women's health	Ottignies-Louvain-la-Neuve
2026-02-02	Optimizing Combined Physical and Cognitive Activity in Community-Dwelling Older Adults.	NCT07630272	Ghent University	No phase (non-drug)	Neurology	Ghent
2026-02-02	Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)	NCT07224360	CSL Behring	Phase 2	Hematology	Brussels
2026-02-02	A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke	NCT07367100	Neuravi	No phase (non-drug)	Neurology	Leuven, Antwerp, Ghent
2026-02-03	Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2	NCT07431281	AstraZeneca	Phase 3	Oncology	Leuven, Brussels, Antwerp, Ghent
2026-02-05	A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)	NCT07222332	Eli Lilly	Phase 3	Endocrinology or metabolism	Leuven, Brussels, Antwerp, Ghent, Liège, Namur, Yvoir (Mont-Godinne)
2026-02-06	A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes	NCT07321886	Eli Lilly	Phase 3	Endocrinology or metabolism	Hasselt
2026-02-06	Prospective Longitudinal Multicentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia	NCT07388966	Sysnav	No phase (non-drug)	Rare or genetic disease	Liège
2026-02-09	Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight	NCT07353931	Eli Lilly	Phase 3	Multiple areas	Leuven, Antwerp, Ghent, Genk, Mechelen
2026-02-10	A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.	NCT07215702	AstraZeneca	Phase 2	Multiple areas	Brussels, Genk, Ottignies-Louvain-la-Neuve
2026-02-10	A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin	NCT07392190	Eli Lilly	Phase 3	Endocrinology or metabolism	Leuven, Brussels, Genk, Kortrijk, Mechelen, Bonheiden, Ostend, Ieper
2026-02-10	A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis	NCT07201922	Boehringer Ingelheim	Phase 3	Respiratory	Leuven, Brussels
2026-02-11	Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life	NCT07143279	Institut Jules Bordet	Phase 1	Endocrinology or metabolism	Brussels
2026-02-11	Pain Associated wIth traditioNal Versus uLtrasound guidEd iuS (Intra Uterine System) inSertion	NCT07315646	Ghent University	No phase (non-drug)	Women's health	Ghent
2026-02-11	A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)	NCT07202546	GSK	Phase 2	Infectious disease	–
2026-02-11	Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS	NCT07197944	Zealand Pharma a/s	Phase 3	Gastroenterology or hepatology	Leuven
2026-02-13	Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders	NCT07509125	UZ Leuven	No phase (non-drug)	Multiple areas	Leuven
2026-02-13	A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis	NCT07298044	Bayer	Phase 4	Cardiovascular	Brussels, Bruges
2026-02-13	A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy	NCT07210723	Kardigan	Phase 2/3	Cardiovascular	Leuven, Brussels, Antwerp, Hasselt, Aalst
2026-02-13	Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy	NCT07215273	Elion Therapeutics	Phase 2	Infectious disease	Leuven, Brussels, Ghent, Bruges
2026-02-15	AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients.	NCT07546188	Hospital Group Saint Joseph Saint Therese and IMTR	No phase (non-drug)	Oncology	Charleroi
2026-02-16	Clinical Performance and Safety Assessment of the Use of iCover Balloon Expandable Covered Stent (iVascular) Implanted as Bridging Stent in FEVAR (Fenestrated Endovascular Aortic Repair) for the Treatment of Complex Abdominal Aortic Aneurysms	NCT07529275	iVascular S.L.U.	No phase (non-drug)	Cardiovascular	Ghent, Liège, Hasselt, Genk, Charleroi, Bonheiden
2026-02-16	Cognitive Model for Behavioral Interventions as a Non-pharmacological Intervention for Behavioral and Psychological Symptoms of Dementia	NCT07356336	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Neurology	Tienen
2026-02-16	A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)	NCT07318558	MSD	Phase 3	Oncology	Leuven, Ghent, Charleroi
2026-02-16	A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)	NCT07220083	Boehringer Ingelheim	Phase 3	Kidney & urology	Leuven, Liège, Aalst
2026-02-18	To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer	NCT07368998	Roche	Phase 2	Oncology	Leuven, Brussels, Hasselt, Namur
2026-02-19	Effect of Foot Position During Rehabilitation of Achilles Tendinopathy on Tendon Mechanics and Symptoms.	NCT07623408	KU Leuven	No phase (non-drug)	Musculoskeletal & rehab	Leuven
2026-02-19	Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases	NCT07703683	UCLouvain	No phase (non-drug)	Endocrinology or metabolism	Brussels
2026-02-19	A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)	NCT07363590	MSD	Phase 1	Immunology or rheumatology	Ghent, Hasselt
2026-02-23	Recognizing Emotional Neglect and Help-Seeking Intention Among Adolescents in Brussels	NCT07365891	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Psychiatry	Brussels
2026-02-24	iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009	NCT06634628	CHDI Foundation	Phase 1	Neurology	Leuven
2026-02-24	A Study of BI 3810944 in Patients With Advanced Cancer	NCT07224425	Boehringer Ingelheim	Phase 1	Oncology	Leuven, Brussels
2026-02-24	AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight	NCT07339423	Novo Nordisk	Phase 3	Endocrinology or metabolism	Leuven, Brussels, Antwerp, Ghent, Roeselare, Mechelen
2026-02-27	A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)	NCT07306559	Boehringer Ingelheim	Phase 1	Oncology	Leuven, Brussels
2026-03-01	Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses	NCT07474025	Institut Jules Bordet	No phase (non-drug)	Oncology	Brussels
2026-03-01	Performance After Cardiac Ablation in Endurance Athletes for Atrial Fibrillation	NCT07726056	KU Leuven	No phase (non-drug)	Cardiovascular	Leuven, Antwerp, Hasselt, Genk

Start	Trial	Registry	Lead sponsor	Phase	Disease area	Belgian sites
2026-03-01	At Home Use of Stimulation Suits for Managing MS Symptoms	NCT07202195	Daphne Kos	No phase (non-drug)	Neurology	Steenokkerzeel (Melsbroek)
2026-03-01	Virtual Reality as a Tool for Training Public Speaking Skills in Higher Education Students	NCT07392554	ULiège	No phase (non-drug)	Other	Liège
2026-03-01	Sedentary Behaviour, Physical Activity Patterns, and Cardiometabolic Health	NCT07419100	Hasselt University	No phase (non-drug)	Multiple areas	Hasselt
2026-03-01	Mobility, Strength, and Functional Outcomes Before Surgery, at 3 Months, and at 6 Months After Hip Arthroscopy for Femoroacetabular Impingement Syndrome	NCT07472400	ULiège	No phase (non-drug)	Musculoskeletal & rehab	Liège
2026-03-01	Bridging the Gap: Implementing BRIDGES	NCT07422909	UCLouvain	No phase (non-drug)	Psychiatry	Brussels
2026-03-01	Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)	NCT07223814	Stichting Hemato-Oncologie voor Volwassenen Nederland	Phase 3	Hematology	Leuven, Brussels, Antwerp, Ghent, Liège, Hasselt, Bruges, Yvoir (Mont-Godinne), Charleroi, Geel, Jolimont
2026-03-02	Ankle vs. Hip vs. Combined Strengthening in Chronic Ankle Instability	NCT07606534	ULiège	No phase (non-drug)	Musculoskeletal & rehab	Liège
2026-03-03	Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules	NCT07237373	Ghent University	No phase (non-drug)	Endocrinology or metabolism	Leuven, Ghent, Bruges
2026-03-04	Polyphenol Metabotypes in People With Diabetes Type 2	NCT06810635	Ghent University	No phase (non-drug)	Endocrinology or metabolism	Ghent
2026-03-04	Auricular Vagus Nerve Stimulation in Patients With High Impact Chronic Low Back Pain	NCT07681336	AZ Maria Middelares	No phase (non-drug)	Musculoskeletal & rehab	Ghent
2026-03-05	Determining the Extent of the Genitourinary Syndrome of Menopause Burden in Breast Cancer Survivors	NCT07563621	Jessa Hospital	No phase (non-drug)	Oncology	Hasselt
2026-03-05	LFP-based Parameter Prediction in DBS for Parkinson's Disease	NCT07485621	Loes Laurijssen	No phase (non-drug)	Neurology	Leuven
2026-03-05	A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer	NCT07284849	Incyte	Phase 3	Oncology	Leuven, Brussels, Antwerp, Ghent, Yvoir (Mont-Godinne)
2026-03-09	A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium	NCT07382440	AbbVie	No phase (non-drug)	Neurology	Leuven, Antwerp, Ghent, Hasselt, Bruges, Roeselare, Kortrijk, La Louvière, Bonheiden, Tournai, Ostend
2026-03-09	A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	NCT07218341	Eli Lilly	Phase 4	Oncology	Roeselare
2026-03-09	Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma	NCT07491445	Revolution Medicines Inc	Phase 3	Oncology	Leuven, Brussels
2026-03-10	Development of Serious Games for Rehabilitation: a Delphi Study	NCT07460778	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Other	Brussels
2026-03-11	Robotic Single Port Ventral Hernia Repair	NCT07755657	AZ Maria Middelares	No phase (non-drug)	Musculoskeletal & rehab	Ghent
2026-03-12	VR-relaxation for ECT-related Anxiety	NCT07546526	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Psychiatry	Brussels
2026-03-12	A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)	NCT07361510	Bristol-Myers Squibb	Phase 3	Oncology	Leuven, Brussels, Antwerp, Brasschaat
2026-03-13	A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation	NCT07412470	Sanofi	Phase 2/3	Immunology or rheumatology	Leuven, Brussels
2026-03-15	Assessing Chronic Pain Patient Preferences	NCT07453524	UCLouvain	No phase (non-drug)	Neurology	Brussels
2026-03-15	MSCS in BURSTDR Patients	NCT07540663	Jessa Hospital	No phase (non-drug)	Neurology	Hasselt
2026-03-16	Evaluation of the Synergistic Effect of Combining a Prebiotic and a Postbiotic on Intestinal Discomfort	NCT07420231	UCLouvain	No phase (non-drug)	Gastroenterology or hepatology	Ottignies-Louvain-la-Neuve
2026-03-16	The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.	NCT07513883	ZOL Genk (Hospital East-Limburg)	Phase 4	Cardiovascular	Genk
2026-03-16	R³ Rehab Pathway Versus Usual Care After Lumbar Radicular Surgery	NCT07313566	UZ Leuven	No phase (non-drug)	Neurology	Leuven, Brussels, Antwerp, Hasselt, Genk, Bruges, Roeselare, Kortrijk, Charleroi, Mechelen, Ottignies-Louvain-la-Neuve, Tournai, Geel, Ieper, Lier, Herentals
2026-03-16	A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes	NCT07351045	Roche	Phase 3	Endocrinology or metabolism	Leuven, Brussels, Liège, Roeselare, Aalst
2026-03-16	Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)	NCT07457580	Sanofi	No phase (non-drug)	Endocrinology or metabolism	Leuven
2026-03-16	BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System	NCT07118358	BIOTRONIK SE und Co KG	No phase (non-drug)	Cardiovascular	Leuven, Liège, Hasselt, Bruges
2026-03-16	A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)	NCT07361497	Bristol-Myers Squibb	Phase 3	Oncology	Leuven, Brussels, Ghent, Genk, Charleroi, Sint-Niklaas, Brasschaat
2026-03-17	A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT	NCT07387367	SymBio Pharmaceuticals Limited	Phase 3	Infectious disease	Leuven, Liège
2026-03-17	Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations	NCT07402057	Ghent University	No phase (non-drug)	Oncology	Ghent, Kortrijk, Aalst
2026-03-19	PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group	NCT07235592	Santen Pharmaceutical Co Ltd	No phase (non-drug)	Ophthalmology	Leuven
2026-03-19	The Effect of CBD on Sleep Quality Following Late Evening Exercise	NCT07570472	KU Leuven	Phase 2	Neurology	Leuven
2026-03-20	Impact of the Reimbursement of Fibrinogen in Cardiac Surgery	NCT07457879	Erasme University Hospital	No phase (non-drug)	Cardiovascular	Brussels
2026-03-23	Physiotherapy Practice in Flemish Nursing Homes	NCT07576751	Hasselt University	No phase (non-drug)	Other	Antwerp, Tongeren
2026-03-23	New Tools and Predictive Markers in the Prognosis of Hypoxic-ischemic Encephalopathy Following Cardiac Arrest	NCT07464938	UCLouvain	No phase (non-drug)	Multiple areas	Brussels
2026-03-23	A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions	NCT07470866	Pfizer	Phase 1	Healthy volunteers	–
2026-03-23	A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF	NCT07429214	Johnson & Johnson	No phase (non-drug)	Cardiovascular	Bruges, Aalst
2026-03-23	Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)	NCT07405164	MSD	Phase 3	Oncology	Leuven
2026-03-23	PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease	NCT07355296	Boehringer Ingelheim	Phase 2	Kidney & urology	Leuven, Brussels, Ghent, Aalst
2026-03-24	A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease	NCT07326709	Novartis Pharmaceuticals	Phase 3	Neurology	Leuven
2026-03-25	Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination	NCT07407569	University of Antwerp	Phase 2	Infectious disease	Leuven, Antwerp, Ghent
2026-03-25	Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy	NCT07144319	Photocure ASA	No phase (non-drug)	Oncology	Leuven
2026-03-25	Belgian Lung Function Study	NCT07419555	KU Leuven	No phase (non-drug)	Respiratory	Leuven, Antwerp, Ghent, Genk, Roeselare
2026-03-26	A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy	NCT07493265	Eisai	Phase 2	Neurology	Ghent
2026-03-26	Evaluation of Dynavisc in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome	NCT06593977	FzioMed Inc	No phase (non-drug)	Neurology	Leuven, Roeselare
2026-03-27	Eccentric Cycling in Multiple Sclerosis Rehabilitation	NCT07316764	ULiège	No phase (non-drug)	Neurology	Liège
2026-03-27	Automated CPET Interpretation: International Validation Study	NCT07534384	KU Leuven	No phase (non-drug)	Healthy volunteers	Leuven, Hasselt, Aalst
2026-03-28	A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease	NCT07571746	AstraZeneca	Phase 2	Kidney & urology	Ieper
2026-03-30	Effects of a Targeted Prevention Program on Change-of-Direction Biomechanics and Performance in Elite Female Soccer Players	NCT07523178	ULiège	No phase (non-drug)	Musculoskeletal & rehab	Liège
2026-03-30	Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer	NCT07736937	Tubulis	Phase 1/2	Oncology	Leuven, Brussels, Ghent, Liège
2026-03-30	InRAD Observational Study	NCT07213700	Stichting International Registry for Alzheimer's Disease and other Dementias Foundation	No phase (non-drug)	Neurology	Leuven
2026-03-31	Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration	NCT07523620	Abbott	No phase (non-drug)	Cardiovascular	Brussels
2026-03-31	A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors	NCT07407933	Sep	Phase 1/2	Oncology	Antwerp, Namur
2026-04-01	International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)	NCT07476729	Charite University Hospital Berlin	Phase 3	Hematology	Ghent
2026-04-01	Back to Work: Perspective of the Employee (Original Language Dutch: Terug-naar-werk: Perspectief Van Werknemer)	NCT07431996	PXL University College	No phase (non-drug)	Other	Hasselt
2026-04-01	The Relationship Between Measured Creatinine Clearance and Acute Kidney Injury in Critically Ill Patients	NCT07624721	Ghent University	No phase (non-drug)	Kidney & urology	Ghent
2026-04-01	Patient Reported Outcome Measurements Registration in Spinal Pathologies and Neuromodulation	NCT07552519	Jessa Hospital	No phase (non-drug)	Musculoskeletal & rehab	Hasselt
2026-04-01	Orthodontic and Articular Effects of the One-Step No-Prep Protocol	NCT07533240	Mainjot Amélie	No phase (non-drug)	Dental & oral	Liège
2026-04-01	Evaluation of a New Articulated Prosthetic Foot: Comfort, Safety and Biomechanics in Individuals With a Lower-Limb Amputation	NCT07530601	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Musculoskeletal & rehab	Brussels
2026-04-01	Effect of Early Versus Late Surgical Intercostal Block on Postoperative Pain Relief Following Video-Assisted Thoracic Surgery (VATS)	NCT07532681	Erasme University Hospital	No phase (non-drug)	Other	Brussels
2026-04-01	Coaching Doctors and Nurses to Improve Ethical Decision-making in Team	NCT07327450	Ghent University	No phase (non-drug)	Other	Ghent
2026-04-01	The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).	NCT07413614	KU Leuven	No phase (non-drug)	Multiple areas	Leuven
2026-04-01	Robotic Single Port Combined Umbilical and Inguinal Hernia Repair	NCT07755696	AZ Maria Middelares	No phase (non-drug)	Musculoskeletal & rehab	Ghent
2026-04-02	Ultrasonographic Vascular Supply	NCT07727707	UZ Leuven	No phase (non-drug)	Dental & oral	Leuven
2026-04-02	Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)	NCT07428499	ADARx Pharmaceuticals	Phase 3	Rare or genetic disease	Antwerp
2026-04-03	Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy	NCT07225270	Genmab AS	Phase 3	Oncology	Leuven
2026-04-04	Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial).	NCT07489274	Ole Hyldegaard	Phase 4	Infectious disease	Antwerp
2026-04-06	A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1	NCT07455383	Perrigo Co Plc	Phase 3	Neurology	Antwerp, Bruges, Namur
2026-04-07	A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation	NCT07535112	Bayer	Phase 1	Oncology	Ghent
2026-04-08	Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)	NCT07298473	Medtronic Cardiac Ablation Solutions	No phase (non-drug)	Cardiovascular	Brussels
2026-04-08	AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors	NCT07403721	Amgen	Phase 1	Oncology	Brussels, Ghent
2026-04-09	A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma	NCT07522073	Incyte	Phase 3	Oncology	Leuven, Brussels, Antwerp, Ghent, Liège, Yvoir (Mont-Godinne), Charleroi
2026-04-10	Comparison Between Different Interdental Brushes in Adults With Periodontal Disease.	NCT07575997	Pierre Fabre SA	No phase (non-drug)	Dental & oral	Brussels
2026-04-13	Exploring the Modulatory Effect of the Dialyzer Membrane Choice on Hemodialysisassociated Thromboinflammation: a Prospective Randomized Cross-over Trial	NCT07682701	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Multiple areas	Brussels
2026-04-13	COmparison of Maintenance of Propofol And Sevoflurane Spectral Study	NCT07561970	UCLouvain	No phase (non-drug)	Neurology	Brussels
2026-04-13	Evaluation of the Bioavailability of Amino Acids From Purple Bacteria	NCT07613983	UCLouvain	No phase (non-drug)	Endocrinology or metabolism	Ottignies-Louvain-la-Neuve
2026-04-13	A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir	NCT07552779	Pfizer	Phase 1	Infectious disease	–
2026-04-14	A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo	NCT07533019	Eli Lilly	Phase 2	Dermatology	Ghent, Liège, Hasselt
2026-04-15	Multicentre Evaluation of Spinal Bone Pathologies Using Zero Echo Time (ZTE) Pseudo-CT MRI Sequences: a Clinical Implementation Study	NCT07844577	UCLouvain	No phase (non-drug)	Musculoskeletal & rehab	Brussels
2026-04-17	Hydrogel Assessment for Local Treatment of Osteoarthritis	NCT07516457	Allegro	No phase (non-drug)	Immunology or rheumatology	Antwerp, Bruges, Roeselare
2026-04-17	Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals	NCT07387328	Ghent University	No phase (non-drug)	Neurology	Ghent
2026-04-17	Effects of a Robot-based Sensorimotor Upper Limb Rehabilitation Paradigm in Chronic Stroke	NCT07547800	KU Leuven	No phase (non-drug)	Neurology	Leuven
2026-04-17	A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression	NCT07546500	K Group Co Ltd	Phase 3	Oncology	Leuven, Brussels
2026-04-17	Identification of Urinary Retention by Simplified Ultrasound: Diagnostic Without Volumetric Measurements	NCT07841821	UCLouvain	No phase (non-drug)	Kidney & urology	Brussels
2026-04-20	Transcultural Digital Solutions in Phase III Cardiac Rehabilitation	NCT07252856	Don Gnocchi Foundation	No phase (non-drug)	Cardiovascular	Leuven
2026-04-20	Acute Power Training Effects in Older Adults	NCT07522398	Hasselt University	No phase (non-drug)	Musculoskeletal & rehab	Hasselt
2026-04-21	Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)	NCT07531095	Amgen	Phase 1	Oncology	Brussels, Antwerp, Ghent
2026-04-21	A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy Adults	NCT07235163	Pfizer	Phase 1	Immunology or rheumatology	–
2026-04-21	AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss	NCT07503210	Novo Nordisk	Phase 3	Endocrinology or metabolism	Liège, Hasselt, Kortrijk, Ostend
2026-04-21	Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe	NCT07585890	University of Groningen	No phase (non-drug)	Gastroenterology or hepatology	Leuven, Brussels, Ghent, Liège
2026-04-21	A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease	NCT07499232	Johnson & Johnson	Phase 3	Gastroenterology or hepatology	Leuven, Brussels, Ghent, Liège, Genk, Roeselare
2026-04-22	Respiratory and Haemodynamic Effects of Conscious Sedation With Dexmedetomidine for a TAVI Procedure	NCT07532733	Erasme University Hospital	No phase (non-drug)	Cardiovascular	Brussels
2026-04-22	A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy Adults	NCT07542886	Pfizer	Phase 1	Endocrinology or metabolism	–
2026-04-22	A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2	NCT07502443	Perrigo Co Plc	Phase 3	Neurology	Antwerp, Bruges, Namur
2026-04-23	GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis	NCT06916390	UZ Leuven	Phase 4	Gastroenterology or hepatology	Leuven
2026-04-23	An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)	NCT07365332	Inhibikase Therapeutics	Phase 3	Cardiovascular	Brussels
2026-04-23	A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)	NCT07419295	MSD	Phase 3	Oncology	Brussels, Ghent, Liège

Start	Trial	Registry	Lead sponsor	Phase	Disease area	Belgian sites
2026-04-23	A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD	NCT07285655	Liquidia Corporation Inc	Phase 3	Multiple areas	Ghent
2026-04-27	A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A	NCT07416604	Roche	Phase 3	Hematology	Leuven, Brussels
2026-04-29	A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)	NCT07545772	Eli Lilly	Phase 2	Gastroenterology or hepatology	Leuven, Brussels, Antwerp, Ghent, Liège, Bruges, Roeselare
2026-04-30	Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP)	NCT07567131	Portal Therapeutics, Inc.	No phase (non-drug)	Rare or genetic disease	Leuven
2026-05-01	Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers	NCT07359742	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Gastroenterology or hepatology	Brussels
2026-05-01	AI-Assisted Endoscopy for Upper Aerodigestive Tract Lesions	NCT07596355	Italian Institute of Technology	No phase (non-drug)	Oncology	Leuven
2026-05-01	Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm	NCT07590986	UCLouvain	No phase (non-drug)	Hematology	Brussels
2026-05-01	Comparative Effectiveness of Alginate, Magaldrate, Sucralfate, Proton Pump Inhibitors, and Diet in Laryngopharyngeal Reflux Disease	NCT07611162	University of Mons	Phase 4	Gastroenterology or hepatology	Mons
2026-05-01	Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context	NCT07621783	Imelda GI Clinical Research Center	No phase (non-drug)	Gastroenterology or hepatology	Bonheiden
2026-05-04	A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease	NCT07483073	Eli Lilly	Phase 2	Gastroenterology or hepatology	Leuven, Ghent, Roeselare
2026-05-04	A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease	NCT07483099	Eli Lilly	Phase 2	Gastroenterology or hepatology	Leuven, Ghent, Roeselare
2026-05-05	Predicting Weight Loss After Pharmacological or Surgical Treatment in Patients With Obesity	NCT07402031	UCLouvain	No phase (non-drug)	Endocrinology or metabolism	Brussels
2026-05-05	Feasibility and Health-economic Evaluation of Remote Clinical Monitoring Enabling Same-day Discharge After Bariatric Surgery	NCT07483775	Jessa Hospital	No phase (non-drug)	Endocrinology or metabolism	Hasselt
2026-05-06	Developing and Testing a Preventive Primary Care Parenting Intervention to Strengthen Parent-Infant Co-Regulation in Families Experiencing Early Regulatory Difficulties	NCT07541716	University of Antwerp	No phase (non-drug)	Psychiatry	Antwerp
2026-05-06	A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)	NCT07549412	Merck KGaA (EMD)	Phase 3	Oncology	Brussels, Charleroi
2026-05-06	A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)	NCT07545759	Eli Lilly	Phase 2	Gastroenterology or hepatology	Leuven, Brussels, Antwerp, Ghent, Liège, Bruges, Roeselare
2026-05-06	A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies	NCT07415031	Mirati Therapeutics Inc	Phase 2	Oncology	Ghent
2026-05-06	Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)	NCT07318597	Regeneron	Phase 2	Cardiovascular	Leuven, Brussels
2026-05-10	Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM)	NCT07237399	Ghent University	No phase (non-drug)	Oncology	Ghent
2026-05-11	Study of INCA036978 in Participants With Myeloproliferative Neoplasms	NCT07441694	Incyte	Phase 1	Hematology	Liège, Roeselare
2026-05-11	A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults	NCT07594769	Pfizer	Phase 1	Neurology	–
2026-05-11	An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)	NCT07517263	Novartis	Phase 3	Cardiovascular	–
2026-05-12	Altered Joint Mechanics and Biological Response in Osteoarthritic Knees.	NCT07481461	UZ Leuven	No phase (non-drug)	Immunology or rheumatology	Leuven
2026-05-12	Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica	NCT07286214	Sanofi	Phase 4	Immunology or rheumatology	Leuven, Brussels, Ghent, Liège, Genk, Bruges
2026-05-13	Sample Collection and Instruction Optimization	NCT07636668	University of Antwerp	No phase (non-drug)	Other	Antwerp
2026-05-13	First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss	NCT07637981	Dendrogenix	Phase 2	Other	Liège
2026-05-13	A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer	NCT07287098	Eli Lilly	Phase 2	Oncology	Leuven, Brussels, Antwerp
2026-05-13	A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies	NCT07572006	Johnson & Johnson	Phase 1	Oncology	Antwerp
2026-05-14	A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis	NCT07571174	Eli Lilly	Phase 1	Neurology	Leuven
2026-05-14	A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)	NCT07571200	Eli Lilly	Phase 1	Neurology	Leuven
2026-05-14	Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1	NCT07486934	Dyne Therapeutics Inc	Phase 3	Rare or genetic disease	Leuven, Antwerp
2026-05-14	A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis	NCT07387549	Ipsen	Phase 3	Gastroenterology or hepatology	Leuven, Brussels, Antwerp, Ghent
2026-05-15	Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.	NCT07455318	Institute of Tropical Medicine	Phase 3	Infectious disease	Brussels, Antwerp, Ghent, Liège
2026-05-15	Change in Platelet Lipid Metabolism and Procoagulant Phenotype Induced by Cardiopulmonary Bypass. Impact on Postoperative Inflammatory Response and Bleeding Complications During Cardiac Surgery.	NCT07630987	UCLouvain	No phase (non-drug)	Cardiovascular	Brussels
2026-05-15	ARTEMIS - The ARTEMIS Cohort	NCT07421219	Region Vastra Gotaland	No phase (non-drug)	Neurology	Leuven
2026-05-17	A Study of TAK-755 in Adults With Acute Ischemic Stroke	NCT07392450	Takeda	Phase 2	Neurology	Ghent, Liège, Genk, Kortrijk
2026-05-18	A First-in-human Study to Assess the Initial Safety, Tolerability, and Effectiveness of the ONSS Bilateral Occipital Nerve Field Stimulation System for the Prophylactic Treatment of Chronic Cluster Headache in Difficult-to-treat Subjects.	NCT07677137	Man and Science, SA	No phase (non-drug)	Neurology	Sint-Niklaas
2026-05-18	Unimanual Versus Bimanual Motor Skill Learning in Acute and Chronic Stroke	NCT07826832	University Hospital of Mont-Godinne	No phase (non-drug)	Neurology	Namur, Yvoir (Mont-Godinne)
2026-05-19	A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF	NCT07428564	Johnson & Johnson	No phase (non-drug)	Cardiovascular	Bruges, Aalst
2026-05-20	CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients	NCT07330323	UZ Leuven	No phase (non-drug)	Oncology	Leuven
2026-05-20	A Study to Test How Different Doses of BI 3814916 Are Tolerated by Healthy People	NCT07486115	Boehringer Ingelheim	Phase 1	Healthy volunteers	Antwerp
2026-05-20	A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)	NCT07124078	Incyte	Phase 2	Immunology or rheumatology	Brussels
2026-05-21	Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents	NCT07554495	Alfasigma S.p.A.	Phase 3	Immunology or rheumatology	Leuven
2026-05-21	RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive	NCT07413939	Roche	Phase 2/3	Oncology	Leuven, Brussels, Antwerp, Hasselt, Kortrijk, Namur, Mechelen
2026-05-21	A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions	NCT07422480	Takeda	Phase 3	Hematology	Leuven, Roeselare, Namur, Yvoir (Mont-Godinne)
2026-05-21	A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight	NCT07564414	Novo Nordisk	Phase 3	Endocrinology or metabolism	Brussels, Roeselare, La Louvière, Mechelen
2026-05-22	A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease	NCT07577843	Johnson & Johnson	Phase 3	Gastroenterology or hepatology	Leuven, Antwerp, Ghent, Roeselare
2026-05-22	First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis	NCT07527923	Regeneron	Phase 1	Dermatology	Leuven
2026-05-22	A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer	NCT07525206	AbbVie	Phase 3	Oncology	Leuven, Brussels, Antwerp, Ghent, Roeselare, Yvoir (Mont-Godinne), Charleroi, Bonheiden
2026-05-23	A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis	NCT07577856	Johnson & Johnson	Phase 3	Gastroenterology or hepatology	Leuven, Brussels, Ghent, Bruges, Bonheiden
2026-05-26	Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.	NCT07666113	UZ Leuven	No phase (non-drug)	Neurology	Leuven
2026-06-01	A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer	NCT07455422	UZA (Antwerp University Hospital)	No phase (non-drug)	Oncology	Antwerp, Ghent, Roeselare
2026-06-01	Effectiveness of the SelfBack-App in Preventing and Treating Low Back Pain Versus no Intervention: a Non-randomized Clinical Trial	NCT07785804	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Musculoskeletal & rehab	Brussels
2026-06-01	Preoperative Genicular Radiofrequency and Functional Outcomes After Total Knee Arthroplasty	NCT07727551	Anesthesiology department Iris South Hospitals	No phase (non-drug)	Immunology or rheumatology	Brussels
2026-06-01	A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction	NCT07192952	Bayer	Phase 3	Cardiovascular	Leuven, Brussels, Antwerp, Ghent, Liège
2026-06-01	Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment	NCT07545486	Centre Hospitalier Interregional Edith Cavell	No phase (non-drug)	Oncology	Brussels, Mons, Charleroi
2026-06-01	Using WoundPilot to Support Wound Care Decisions in Patients With Chronic Wounds	NCT07562269	Ghent University	No phase (non-drug)	Dermatology	Ghent
2026-06-01	GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP)	NCT07594639	AgNovos Healthcare	No phase (non-drug)	Endocrinology or metabolism	Sint-Niklaas
2026-06-01	User Evaluation Think Life	NCT07654127	Ghent University	No phase (non-drug)	Psychiatry	Ghent
2026-06-01	Cerebellar Research in Ultrasound Stimulation	NCT07508696	KU Leuven	No phase (non-drug)	Neurology	Leuven
2026-06-01	Deep Learning Framework for Continuous Depth of Anesthesia Forecasting	NCT07536230	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Other	Bruges
2026-06-01	Implementation and Evaluation of a Complex Intervention to Reduce Avoidable Transitions Between Nursing Home and Hospital	NCT07359521	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Dental & oral	Ghent, Dendermonde, Eeklo, Lokeren
2026-06-01	Boosted Compression for Lower Limb Chronic Edema	NCT07708662	University of Antwerp	No phase (non-drug)	Other	Leuven, Antwerp, Ghent
2026-06-01	Cardiac Surgery, the Incidence and Impact of Chronic postOperative Pain: a Survey	NCT07640646	UZ Leuven	No phase (non-drug)	Cardiovascular	Leuven
2026-06-01	Impact of Leisure Activities on Quality of Life in Low Back Pain	NCT07467499	Centre Hospitalier Valida	No phase (non-drug)	Musculoskeletal & rehab	Brussels, Charleroi
2026-06-03	Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma	NCT07674498	Institut Jules Bordet	No phase (non-drug)	Hematology	Brussels
2026-06-04	The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity	NCT06494878	University of Calgary	Phase 3	Cardiovascular	Brussels
2026-06-04	Assessment of a New Tool to Measure Tongue Muscle Function	NCT07625761	UCLouvain	No phase (non-drug)	Musculoskeletal & rehab	Brussels
2026-06-05	A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults	NCT07526116	Regeneron	Phase 1	Healthy volunteers	Ghent
2026-06-05	Targeting Muscle Strength Loss Due to Hospitalization in Older Adults by Blood-flow Restriction Combined With an Electromyography-driven Serious Game.	NCT07294131	VUB (Vrije Universiteit Brussel)	Phase 2	Musculoskeletal & rehab	Leuven, Brussels, Antwerp
2026-06-08	Holistic Evaluation of Approaches to Long-term Health & Survivorship	NCT07745205	Institut Jules Bordet	No phase (non-drug)	Oncology	Brussels
2026-06-08	Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments	NCT07468071	Novartis Pharmaceuticals	Phase 1/2	Oncology	Leuven, Sint-Niklaas
2026-06-08	Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD	NCT07652294	Spyre Therapeutics	Phase 2	Gastroenterology or hepatology	Ghent
2026-06-10	Prospective Evaluation of New Metrics to Assess Cardiovascular Remodeling in Obstructive Sleep Apnea	NCT07427589	UZA (Antwerp University Hospital)	No phase (non-drug)	Multiple areas	Antwerp
2026-06-12	Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease	NCT07514338	Pharming Technologies B.V.	Phase 2	Rare or genetic disease	Leuven, Brussels, Ghent
2026-06-15	The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery	NCT07524062	UZ Leuven	No phase (non-drug)	Dermatology	Leuven
2026-06-15	Comparing Two Training Methods for Learning Robot-Assisted Radical Prostatectomy	NCT07669974	ORSI Academy asl	No phase (non-drug)	Oncology	Melle
2026-06-15	Microwave Intervention Under Local Anesthesia	NCT07412275	Koelis	No phase (non-drug)	Oncology	Brussels
2026-06-18	OPTION-EMEA Clinical Trial	NCT07349121	Boston Scientific Corp	No phase (non-drug)	Cardiovascular	–
2026-06-20	High-Flow Tracheal Therapy on Tracheobronchial Secretions in Tracheostomized Patients	NCT06897319	UCLouvain	No phase (non-drug)	Respiratory	Brussels
2026-06-23	Flash Radiotherapy for Skin Cancer	NCT07455331	Institut Jules Bordet	Phase 2	Oncology	Brussels
2026-06-23	Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum	NCT07342608	MicroPort Scientific Corporation	No phase (non-drug)	Cardiovascular	Ghent
2026-06-25	A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants	NCT07655518	Bristol-Myers Squibb	Phase 1	Neurology	Leuven
2026-06-26	Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab	NCT07039422	Novartis	Phase 2	Hematology	–
2026-06-26	Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests	NCT07106632	National Federation of French Cancer Centres	Phase 3	Oncology	Brussels, Namur, Charleroi, La Louvière, Ottignies-Louvain-la-Neuve, Verviers
2026-06-29	An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis	NCT07665723	Roche	Phase 1	Gastroenterology or hepatology	Leuven, Roeselare
2026-06-30	HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer	NCT06595563	Institut Jules Bordet	Phase 2	Oncology	Leuven, Brussels, Ghent, Liège, Roeselare, Charleroi
2026-07-01	VIPPSTAR-G1 Digital Early Intervention for Visual Impairment	NCT07717671	University of Brescia	No phase (non-drug)	Ophthalmology	Leuven
2026-07-01	Long-term Aseptic Revision & Advanced Hip Arthroplasty Database	NCT07481448	UZ Leuven	No phase (non-drug)	Musculoskeletal & rehab	Leuven
2026-07-01	A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis	NCT07020715	UZA (Antwerp University Hospital)	Phase 2	Neurology	Antwerp
2026-07-01	Intrathecal Therapy Versus Standard Care for Severe Cancer Pain	NCT07691840	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Oncology	Brussels
2026-07-01	The Effect of Mental Fatigue on Upper Extremity Functional Performance	NCT07645404	Bakircay University	No phase (non-drug)	Healthy volunteers	Brussels
2026-07-01	Mental Fatigue Effects on Posture and Spinal Reflexes	NCT07650903	Bakircay University	No phase (non-drug)	Healthy volunteers	Brussels
2026-07-01	Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The Colorectal Regular-Irregular Score	NCT07584486	Ghent University	No phase (non-drug)	Oncology	Ghent
2026-07-01	Corpus Luteum Function and Cardiovascular Adaptation in a Natural MOCK Cycle.	NCT07648381	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Women's health	Brussels
2026-07-01	Evaluation of the 5C® MEDic Knee System	NCT07491575	UZ Leuven	No phase (non-drug)	Musculoskeletal & rehab	Leuven

Start	Trial	Registry	Lead sponsor	Phase	Disease area	Belgian sites
2026-07-01	The Value of Spleen Stiffness Measurement in Patients With PBC	NCT07319169	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Gastroenterology or hepatology	Brussels
2026-07-01	Chronic Low Back Pain Comorbidities: Unravelling Impaired Glucose Metabolism	NCT07734714	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Multiple areas	Brussels
2026-07-01	Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults	NCT07727694	UZ Leuven	No phase (non-drug)	Multiple areas	Leuven, Brussels, Antwerp, Ghent, Liège
2026-07-01	Acute Effects of Post-Exercise Hyperoxia on Recovery in Cycling	NCT07659301	UCLouvain	No phase (non-drug)	Healthy volunteers	Ottignies-Louvain-la-Neuve
2026-07-01	Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon	NCT07650578	University of Mons	No phase (non-drug)	Cardiovascular	Brussels, Liège, Mons, Charleroi, Bonheiden, Libramont
2026-07-01	Clinical Decision-Making in FAIS	NCT07536295	UZ Leuven	No phase (non-drug)	Musculoskeletal & rehab	Leuven
2026-07-01	A Single Arm Trial to Evaluate the Safety and Efficacy of the Long (> 150mm) PasseoTM-18 LuxTM Drug-coated Balloon in the Treatment of Subjects With Infrainguinal Stenotic, Restenotic or Occlusive Lesions	NCT07385573	KANDO Research	No phase (non-drug)	Cardiovascular	Genk, Aalst, Bonheiden, Dendermonde
2026-07-01	Pridopidine Phase 3 Study in Huntington's Disease	NCT07609108	Prilenia Therapeutics BV	Phase 3	Neurology	Brussels
2026-07-02	A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer	NCT07365241	AbbVie	Phase 3	Oncology	Roeselare
2026-07-06	A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)	NCT07630974	MSD	Phase 1/2	Oncology	Ghent
2026-07-07	LEOPARD Prospective Validation Cohort 1	NCT06723275	Public Assistance Hospitals Paris	No phase (non-drug)	Gastroenterology or hepatology	Ghent
2026-07-07	Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation	NCT07575269	Boston Scientific Corp	No phase (non-drug)	Cardiovascular	Bruges
2026-07-08	A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With the TRUPULSE™ Generator for Treatment of Ventricular Arrhythmias	NCT07727057	Johnson & Johnson	No phase (non-drug)	Cardiovascular	Bruges, Aalst
2026-07-10	DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy	NCT07544654	Boehringer Ingelheim	Phase 3	Oncology	Leuven, Brussels, Antwerp, Liège
2026-07-13	Study of AT-587 in Healthy Subjects	NCT07728487	Atea Pharmaceuticals	Phase 1	Infectious disease	Antwerp
2026-07-14	A Study to Learn About How Different Forms of Study Medicine Prifetrastat Are Taken Up Into the Blood in Healthy Adults	NCT07721402	Pfizer	Phase 1	Healthy volunteers	–
2026-07-14	A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome	NCT07503444	UCB BIOSCIENCES, Inc.	Phase 3	Rare or genetic disease	Brussels
2026-07-15	The HYCORE1 Trial: Hybrid Revascularization Versus Coronary Artery Bypass Grafting	NCT05504031	Copenhagen University Hospital	No phase (non-drug)	Cardiovascular	Leuven
2026-07-19	Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)	NCT07227805	Medtronic plc	No phase (non-drug)	Endocrinology or metabolism	Leuven, Brussels, Antwerp
2026-07-21	A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)	NCT07366034	Boehringer Ingelheim	Phase 3	Respiratory	Brussels
2026-07-23	Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study	NCT06990061	European Organisation for Research and Treatment of Cancer	No phase (non-drug)	Oncology	Brussels, Antwerp
2026-07-23	A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity	NCT07725809	Pfizer	Phase 1	Endocrinology or metabolism	–
2026-07-24	Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment	NCT07444567	AstraZeneca	Phase 3	Multiple areas	Brussels, Antwerp
2026-07-27	A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)	NCT07492680	Bristol-Myers Squibb	Phase 2	Oncology	Brussels, Ghent
2026-07-27	A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis	NCT07497087	Boehringer Ingelheim	Phase 3	Immunology or rheumatology	Leuven, Brussels, Ghent, Liège, Yvoir (Mont-Godinne)
2026-07-29	Iron Deficiency at ICU Discharge	NCT07781540	University of Ferrara	No phase (non-drug)	Hematology	Brussels
2026-07-30	Digital Monitoring of Upper Limb Function in Non-Ambulant DMD	NCT07664124	ULiège	No phase (non-drug)	Rare or genetic disease	Liège
2026-07-30	The Leuven Longitudinal Late-Life Depression Study	NCT07768098	UZ Leuven	No phase (non-drug)	Psychiatry	Leuven
2026-08-01	A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.	NCT07357675	EBI Anti Sepsis BV	Phase 3	Cardiovascular	Ghent
2026-08-01	Natural History Study for Patients With Nemaline Myopathy in Belgium	NCT07201636	ULiège	No phase (non-drug)	Rare or genetic disease	Liège
2026-08-01	A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)	NCT07742735	VectivBio AG	Phase 3	Gastroenterology or hepatology	Leuven, Antwerp
2026-08-01	Smartphone Based-PPG Assessment of REconversion in Persistent Atrial Fibrillation	NCT07752940	ZOL Genk (Hospital East-Limburg)	No phase (non-drug)	Cardiovascular	Leuven, Genk
2026-08-01	Quality of Life, Psychosocial Burden, and Structural-functional Status in Adults With Spinal Deformity.	NCT07749534	UZ Leuven	No phase (non-drug)	Musculoskeletal & rehab	Leuven
2026-08-01	Evaluation of a Specialised Tracheostomy Team for the Management of Patients With a Tracheostomy Cannula in a Belgium General Hospital: A Retrospective Study.	NCT07755969	Vitaz	No phase (non-drug)	Respiratory	Sint-Niklaas
2026-08-01	Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)	NCT07682129	Entrada Therapeutics	Phase 2	Rare or genetic disease	Leuven, Ghent, Liège
2026-08-01	Neuromuscular Function and Performance in Athletes With or Without Bruxism	NCT07556211	Mainjot Amélie	No phase (non-drug)	Musculoskeletal & rehab	Liège
2026-08-01	The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment	NCT07788573	UCLouvain	No phase (non-drug)	Neurology	Brussels
2026-08-02	Minimal ACCess Hernia InguinAlis Treatment of Hernia	NCT07756749	AZ Maria Middelares	No phase (non-drug)	Musculoskeletal & rehab	Ghent
2026-08-05	Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study	NCT07746895	Swedish Orphan Biovitrum AB	Phase 4	Rare or genetic disease	Leuven, Brussels, Antwerp, Liège, Namur, Charleroi
2026-08-10	Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants	NCT07636551	Institute of Tropical Medicine	No phase (non-drug)	Infectious disease	Antwerp
2026-08-10	A Study Comparing an Investigational Wound Gel With Standard Treatment for Mild to Moderate Diabetic Foot Ulcers	NCT07783087	Flen Health SA	No phase (non-drug)	Endocrinology or metabolism	Leuven, Ghent, Liège, Bruges, Charleroi, Mechelen, Bonheiden, Arlon
2026-08-11	Inter-Limb Transfer in Acute Stroke	NCT07822633	University Hospital of Mont-Godinne	No phase (non-drug)	Neurology	Brussels, Namur, Yvoir (Mont-Godinne)
2026-08-12	Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight	NCT07770841	Novo Nordisk	Phase 3	Endocrinology or metabolism	Brussels, Ghent, Bonheiden
2026-08-13	Targeted Temperature Management at 33°C Versus Controlled Normothermia for In-hospital Cardiac Arrest	NCT07086703	Nantes University Hospital	No phase (non-drug)	Cardiovascular	Brussels, Ghent, Charleroi, Ottignies-Louvain-la-Neuve
2026-08-15	Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)	NCT07681713	PTC Therapeutics Inc	Phase 3	Rare or genetic disease	Brussels
2026-08-15	Microbiome, Dietary and Quality of Life Analysis of People Living With CVID Treated With or Without Immunoglobulins.	NCT07844668	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Immunology or rheumatology	Brussels, Ninove
2026-08-18	A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation	NCT07625215	Bayer	Phase 2	Cardiovascular	Leuven, Hasselt, Roeselare
2026-08-18	Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut	NCT07655375	Guy Boeckxstaens	No phase (non-drug)	Gastroenterology or hepatology	Leuven
2026-08-25	Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-pump Coronary Artery Bypass Grafting	NCT07314138	Catharina Hospital	No phase (non-drug)	Cardiovascular	Leuven
2026-08-26	A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy	NCT07771465	Kardigan	Phase 3	Cardiovascular	Leuven, Brussels, Antwerp, Hasselt, Aalst
2026-08-31	Study of Combined GARP:TGF-β1/PD-1 Blockade as a Shock-and-kill Strategy in HIV-1 Cure	NCT07692932	UCLouvain	No phase (non-drug)	Infectious disease	Brussels
2026-08-31	A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus	NCT07630714	AstraZeneca	Phase 2	Immunology or rheumatology	Leuven, Brussels, Ghent, Liège
2026-08-31	Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment	NCT07691970	AstraZeneca	Phase 3	Immunology or rheumatology	Ghent
2026-09-01	Randomized Clinical Investigation of Photobiomodulation (PBM) for the Management of Early Peripheral Neuropathy Related to Medical Oncologic Therapy	NCT07681921	Institut Jules Bordet	No phase (non-drug)	Neurology	Brussels
2026-09-01	Ultrasound Assessment of Tongue Characteristics in Adolescents With Obesity and Obstructive Sleep Disorders	NCT07613944	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Multiple areas	Brussels
2026-09-01	The Tooth Collar Technique	NCT07753525	UZ Leuven	No phase (non-drug)	Dental & oral	Leuven, Aalst
2026-09-01	Effects of Physiotherapy on Ultrasound and Clinical Parameters in Women With Dysmenorrhea	NCT07645196	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Women's health	Brussels
2026-09-01	New Consciousness Indicators (NCI)	NCT07786298	ULiège	No phase (non-drug)	Neurology	Liège
2026-09-01	SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates	NCT07474558	Institut Jules Bordet	Phase 2	Oncology	Brussels, Namur, Mons
2026-09-01	A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes	NCT07668336	Eli Lilly	Phase 3	Endocrinology or metabolism	Leuven, Brussels, Ghent
2026-09-01	Targeted Muscle Activation During Strength Training for Children With CP	NCT07800221	UZ Leuven	No phase (non-drug)	Neurology	Leuven
2026-09-01	Collaborative Clinical Reasoning: Perceptions and Practices of General Practitioners, Physical Therapists, and Patients With Low Back Pain in Primary Care	NCT07802951	UCLouvain	No phase (non-drug)	Musculoskeletal & rehab	Brussels
2026-09-01	Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation	NCT07436299	Oslo University Hospital	No phase (non-drug)	Cardiovascular	Leuven, Aalst
2026-09-01	Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation	NCT07405671	UZ Leuven	Phase 4	Cardiovascular	Leuven, Antwerp, Aalst
2026-09-01	Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)	NCT07817875	Eli Lilly	Phase 3	Endocrinology or metabolism	Leuven, Brussels
2026-09-01	Healthy Adaptation to Pregnancy, Postpartum and Parenthood	NCT07837193	KU Leuven	No phase (non-drug)	Multiple areas	Leuven
2026-09-01	PRotEin Provision in Critical IllneSs -2	NCT07529522	ZOL Genk (Hospital East-Limburg)	No phase (non-drug)	Other	Antwerp, Genk
2026-09-01	Natural History Study of Advanced RCD	NCT07854899	SparingVision	No phase (non-drug)	Ophthalmology	Ghent
2026-09-01	A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping	NCT07587242	Avidity Biosciences	Phase 3	Rare or genetic disease	Leuven, Liège
2026-09-01	Hybrid Telerehabilitation for Anterior Knee Pain in Routine Physiotherapy Practice	NCT07842913	Farraj Miguel	No phase (non-drug)	Musculoskeletal & rehab	Brussels
2026-09-01	Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease	NCT05865379	TRB Chemedica International SA	No phase (non-drug)	Ophthalmology	Leuven
2026-09-02	Optimizing Gait Rehabilitation After Stroke	NCT07798388	Ghent University	No phase (non-drug)	Neurology	Antwerp, Ghent, Hasselt
2026-09-08	A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia	NCT07623200	Incyte	Phase 3	Hematology	Leuven, Brussels, Liège, Roeselare
2026-09-10	Rehabilitation Through Individualized Support and Exercise	NCT07857096	UZ Leuven	No phase (non-drug)	Oncology	Leuven
2026-09-10	A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib	NCT07623161	Takeda	Phase 3	Hematology	Leuven, Antwerp, Roeselare, Yvoir (Mont-Godinne), La Louvière
2026-09-11	A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum	NCT07811193	Bayer	Phase 2	Oncology	Leuven, Brussels, Ghent, Roeselare, La Louvière
2026-09-14	Identification of Changes in Cancer-related Fatigue and Physical Activity and Their Association in Patients With Inoperable Lung Cancer: a Longitudinal Observational Study	NCT07799974	Ghent University	No phase (non-drug)	Oncology	Ghent
2026-09-15	Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies	NCT07648264	CSL Behring	Phase 3	Multiple areas	Antwerp, Ghent, Liège, Roeselare
2026-09-15	A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis	NCT07412704	Bristol-Myers Squibb	Phase 1/2	Immunology or rheumatology	Leuven, Antwerp
2026-09-17	FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression	NCT07540988	Boehringer Ingelheim	Phase 3	Respiratory	Leuven, Liège, Roeselare
2026-09-17	A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer	NCT07701941	Daiichi Sankyo	Phase 1/2	Oncology	Leuven, Brussels
2026-09-21	A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours)	NCT07744152	Boehringer Ingelheim	Phase 1	Oncology	Leuven
2026-09-30	Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer	NCT07808151	Solstice Oncology, Inc.	Phase 2	Oncology	Leuven, Brussels, Ghent, Liège, Bonheiden, Ostend
2026-10-01	Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus	NCT07559188	Azalea Vision	No phase (non-drug)	Ophthalmology	Antwerp
2026-10-01	Effect of Continuous Nebulisation of Isotonic Saline Solution Combined With Heated Humidification on Mucociliary Clearance in Healthy Subjects	NCT07722377	UCLouvain	No phase (non-drug)	Respiratory	Brussels
2026-10-01	Oral Versus Intravenous Tranexamic Acid in Off-Pump Coronary Artery Bypass Surgery	NCT07740330	Clinique Saint-Luc	Phase 4	Cardiovascular	Brussels
2026-10-01	A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours	NCT07688148	Apmonia Therapeutics	Phase 1/2	Oncology	Brussels, Ghent
2026-10-01	A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer	NCT07711067	ElmediX	Phase 2/3	Oncology	Antwerp, Ghent
2026-10-01	Impact of Continuous Isotonic Saline Nebulisation Combined With Heated Humidification on the Rheology of Bronchial Secretions.	NCT07617142	UCLouvain	No phase (non-drug)	Respiratory	Brussels
2026-10-01	Long-term Follow-up of Actifit® Meniscal Scaffold Patients.	NCT07800923	Orteq Sports Medicine	No phase (non-drug)	Musculoskeletal & rehab	Ghent
2026-10-01	Cycle-to-cycle Variability of Progesterone in the Endometrium in Patients Undergoing an Euploid Blastocyst Transfer in a Hormone Replacement Therapy (HRT) Cycle (PROMICOFET)	NCT07818278	Ghent University	Phase 4	Women's health	Ghent
2026-10-01	Partial Range Of Field IOLs in DMEK-Enabled Procedures	NCT07441616	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Ophthalmology	Leuven
2026-10-01	Coffee Use, Physical Activity and Symptomatic Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction and an ICD	NCT07823998	Jean-Benoît Le Polain de Waroux	No phase (non-drug)	Cardiovascular	Bruges
2026-10-01	Exploring the Effect of the Hypershell Hip Exoskeleton on Fatiguing, Everyday Activities in Older Adults	NCT07840872	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Musculoskeletal & rehab	Brussels
2026-10-01	Positive Events Training to Enhance Positive Emotions in Adolescents With Elevated Depressive Symptoms: An N=1 Trial	NCT07825285	KU Leuven	No phase (non-drug)	Psychiatry	Leuven
2026-10-01	The Impact of Indoor Environmental Quality on Symptoms in Patients With Chronic Obstructive Pulmonary Disease	NCT07799896	ZOL Genk (Hospital East-Limburg)	No phase (non-drug)	Respiratory	Genk

Start	Trial	Registry	Lead sponsor	Phase	Disease area	Belgian sites
2026-10-01	Music Intervention to Reduce Anxiety and Prevent Delirium in Older Adults Undergoing Cardiac Surgery	NCT07851194	KU Leuven	No phase (non-drug)	Multiple areas	Leuven
2026-10-05	A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)	NCT07843940	Boehringer Ingelheim	Phase 1/2	Oncology	Brussels, Ghent
2026-10-15	Effect of Left Paratracheal Pressure on Cerebral Oxygenation During General Anesthesia	NCT07778303	Clinique Saint-Luc	No phase (non-drug)	Neurology	Brussels
2026-10-15	A Study to Evaluate the Safety and Feasibility of Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation in a Cohort Critical Ill Patients With Acute Kidney Injury and Presumed Absent Citrate Metabolism	NCT07751874	UZA (Antwerp University Hospital)	No phase (non-drug)	Kidney & urology	Antwerp
2026-10-19	DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers	NCT07707895	Boehringer Ingelheim	Phase 1/2	Oncology	Antwerp, Ghent
2026-10-26	A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer	NCT07851103	Boehringer Ingelheim	Phase 1	Oncology	Ghent
2026-11-01	Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)	NCT07782112	Canton of Ticino Cantonal Hospital Group	Phase 3	Oncology	Brussels, Antwerp, Hasselt, Bruges, Kortrijk, Aalst, Mechelen
2026-11-01	Simulation-Based Intrathecal Pump Refill Training	NCT07854834	VUB (Vrije Universiteit Brussel)	No phase (non-drug)	Neurology	Brussels
2026-11-09	A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies	NCT07789015	Boehringer Ingelheim	Phase 3	Immunology or rheumatology	Leuven, Brussels, Ghent, Liège
2026-12-16	Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis	NCT07441408	Bristol-Myers Squibb	Phase 3	Respiratory	Leuven, Brussels, Liège, Kortrijk, Yvoir (Mont-Godinne)
2026-12-31	Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations	NCT07738887	Lysarc	Phase 2	Hematology	Leuven, Brussels, Ghent, Namur, La Louvière
2026-12-31	A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)	NCT07848295	Bristol-Myers Squibb	Phase 1	Oncology	Leuven, Ghent

ABOUT

How this report was made

Data

All clinical trials in AcademicLabs with a listed location in Belgium and a registered start date between 1 January and 31 December 2026, as of 8 October 2026 (398 trials). Records come from public registries such as ClinicalTrials.gov, the EU Clinical Trials Register and the WHO trial registry.

AI reads, code counts

AcademicLabs AI read each registry record on its own, with no web search and no facts from model memory, and answered a fixed set of questions: disease area, intervention, development stage, sponsor type, Belgian sites and Belgian sponsorship. Counting, city and region matching and every figure were then done in code. Lead sponsor type uses the first listed sponsor.

Read with care

These are registered plans, not results. Most trials are recruiting or not yet open, and enrollment is missing for most records. In 12 trials no named Belgian city could be confirmed. Brussels covers the 19 municipalities of the Brussels-Capital Region (including Jette, Anderlecht and Woluwe); Antwerp includes Edegem (UZA) and Wilrijk. Start dates and statuses are self-reported by sponsors.

How to cite

AcademicLabs (2026). Clinical Trials in Belgium 2026. Arne Smolders. https://academiclabs.com/research-reports/belgium-clinical-trials-2026. Data as of 8 October 2026.

Data and figures are licensed CC BY 4.0: free to reuse with credit “Source: AcademicLabs”. Open the underlying search on AcademicLabs.

RESEARCHERS

Researchers running the trials

85 of the 398 trials name an investigator with a Belgian affiliation in the registry record: 90 researchers in total. Industry trials rarely name one, so this list mostly reflects academic and hospital-led studies.

Investigator	Affiliation	Trials	Disease areas
Copine Sylvie	UCLouvain	4	Endocrinology or metabolism, Gastroenterology or hepatology, Healthy volunteers, Women's health
Bart Roelands	VUB	3	Healthy volunteers, Women's health
Eva Swinnen	VUB	3	Musculoskeletal & rehab, Other
Laurent Simar	UCLouvain	3	Endocrinology or metabolism, Gastroenterology or hepatology, Women's health
Andy Temmerman	KU Leuven	2	Dental & oral
Benjamin Javillier	Clinique Saint-Luc Bouge	2	Cardiovascular, Neurology
Christophe Beauloye	UCLouvain	2	Cardiovascular
Gwendolyn Portzky	Ghent University	2	Psychiatry
Laurent Servais	UCLouvain	2	Rare or genetic disease
Louise Deldicque	UCLouvain	2	Gastroenterology or hepatology, Women's health
Stijn Ghijselings	KU Leuven	2	Musculoskeletal & rehab
William Poncin	UCLouvain	2	Musculoskeletal & rehab, Respiratory
Wim Janssens	KU Leuven	2	Healthy volunteers, Respiratory
Yves Vandermeeren	UCLouvain	2	Neurology
Alexander De Greef	KU Leuven	1	Dental & oral
Alexandre Mottrie	Orsi Academy	1	Oncology
Amandine Everard	UCLouvain	1	Endocrinology or metabolism
Ana Belén Salamanca Castro	KU Leuven	1	Dental & oral
Ann Smeets	KU Leuven	1	Oncology
Annemiek Leeman	KU Leuven	1	Dermatology
Arnaud Philippot	KU Leuven	1	Psychiatry
Bertrand Tombal	UCLouvain	1	Oncology
Bruno Lapauw	Ghent University	1	Endocrinology or metabolism
Bruno Tassignon	VUB	1	Musculoskeletal & rehab
C. Van Aelbrouck	ULB	1	Cardiovascular
Christine Desmedt	KU Leuven	1	Oncology
Céline Boudart	Hôpital Erasme (H.U.B)	1	Cardiovascular
Daniel Langer	KU Leuven	1	Respiratory
Daphne Kos	VUB	1	Neurology
David James Tate	Ghent University	1	Oncology
David Ruttens	ZOL Genk	1	Respiratory
Dimitri Beeckman	Ghent University	1	Dermatology
Edwin Wouters	Institute of Tropical Medicine	1	Psychiatry
Elisabeth De Waele	VUB	1	Infectious disease
Evelien Van Roie	KU Leuven	1	Musculoskeletal & rehab
Filip Muysoms	AZ Maria Middelares	1	Musculoskeletal & rehab
Filip Raes	KU Leuven	1	Psychiatry
Florence Souard	ULB	1	Oncology
Florine Janssens	VUB	1	Multiple areas
Frédéric Lecouvet	UCLouvain	1	Musculoskeletal & rehab
Gabriel Liberale, MD, PhD	Institut Jules Bordet	1	Oncology
Geert Verheyden	VIB-KU Leuven	1	Oncology
Greet Cardon	Ghent University	1	Neurology
Guido Claessen	Hartcentrum Hasselt	1	Cardiovascular
Guy Boecxkstaens	KU Leuven	1	Gastroenterology or hepatology
Hans Van Veer	KU Leuven	1	Respiratory
Harry (GH) Van Lenthe	KU Leuven	1	Immunology or rheumatology
Hazem Wafa	KU Leuven	1	Musculoskeletal & rehab
Hilde Beele	Ghent University	1	Dermatology
Ionut Tabolcea	ULB	1	Cardiovascular
Irina Spacova	Antwerp Province	1	Respiratory
Jean Cyr Yombi	UCLouvain	1	Infectious disease
Jo Nijs	VUB	1	Multiple areas
Johan Verbraecken	University of Antwerp	1	Respiratory
Joke Spildooren	Hasselt University	1	Other
Jonathan Krygier	ULB	1	Dermatology
Kaat Desloovere	KU Leuven	1	Neurology
Karim Touihri	CHIREC Edith Cavell	1	Musculoskeletal & rehab
Karolien Termote	VUB	1	Ophthalmology
Kim Van Hoorenbeeck	Antwerp Province	1	Respiratory
Koen Huysentruyt	VUB	1	Gastroenterology or hepatology
Koen Milisen	KU Leuven	1	Multiple areas
Köppen	UZA	1	Ophthalmology
Laura Polastro	Institut Jules Bordet	1	Oncology
Laurens J. Ceulemans	KU Leuven	1	Respiratory
Laurens Liesenborghs	KU Leuven	1	Infectious disease
Laurent Pison	ZOL Genk	1	Cardiovascular
Lorenz Seyssens	Ghent University	1	Dental & oral
Manon de Montigny	UCLouvain	1	Other
Marc Francaux	UCLouvain	1	Psychiatry
Marie Y. Detrait	Groupe Jolimont / Saint-Joseph (Gilly)	1	Oncology
Martine Piccart	Institut Jules Bordet	1	Oncology
Mathilde Devits	ULiège	1	Musculoskeletal & rehab
Niki Rashidian	Orsi Academy	1	Oncology
Olivia Dalleur	UCLouvain	1	Other
Peter Haemers	KU Leuven	1	Cardiovascular
Piet Dirix	Iridium Network (Antwerp)	1	Oncology
Piet Ost	Ghent University	1	Oncology
Selena Toma	UCLouvain	1	Dental & oral
Sofie Heylen	UCLouvain	1	Oncology
Sophie Lucas	UCLouvain	1	Infectious disease
Stephane Carlier	University of Mons	1	Cardiovascular
Steven Provyn	VUB	1	Women's health
Steven Smet	Ghent University	1	Dermatology
Steven Weyers	Ghent University	1	Women's health
Stéphanie Hody	ULiège	1	Neurology
Tinne Smets	VUB	1	Dental & oral
Virginie De Wilde	Hôpital Erasme (H.U.B)	1	Hematology
Wouter Oosterlinck	KU Leuven	1	Cardiovascular
Yanina J.L. Jansen	KU Leuven	1	Respiratory

Key questions

How many clinical trials start in Belgium in 2026?

AcademicLabs found 398 clinical trials with Belgian involvement and a registered start date in 2026, as of 8 October 2026. 191 of them (48%) run only in Belgium; the other 197 are international trials with Belgian sites. Registries keep adding trials after they start, so the count for late 2026 will still grow.

Which Belgian cities host the most new clinical trials?

Brussels has a site in 172 of the 398 trials, Leuven in 160 and Ghent in 104, followed by Antwerp (79) and Liège (57). By region, 280 trials have a site in Flanders, 172 in the Brussels-Capital Region and 94 in Wallonia. A multi-site trial counts in every city where it runs.

Who sponsors clinical trials in Belgium?

Universities and hospitals lead 201 of the 398 trials (51%) and industry leads 187 (47%). 174 trials have a Belgian sponsor; the most active are VUB (Vrije Universiteit Brussel) (26), UCLouvain (26) and UZ Leuven (23). The most active companies are Boehringer Ingelheim (16), Eli Lilly (16), Bristol-Myers Squibb (8).

Which diseases do the 2026 Belgian trials study?

Oncology is the largest area with 81 trials (20%), followed by neurology (45) and cardiovascular disease (42). 54% of all trials have no drug-development phase: they test medical devices, surgery, diagnostics, digital tools and care pathways rather than a new medicine.

How many trials run only in Belgium?

191 trials (48%) list Belgium as their only country, and almost all of them are led by Belgian universities and hospitals. 87% of industry-led trials are international.

Which countries share the most clinical trials with Belgium?

Of the 197 international trials, 134 (68%) also run in the United States, 123 in Spain, 122 in France and 113 in Germany.

Are there obesity drug trials in Belgium in 2026?

Yes. 13 trials target obesity or excess weight, 11 of them run by industry, including studies by Novo Nordisk, Eli Lilly and Roche, some in children and adolescents.

Which researchers lead clinical trials in Belgium in 2026?

85 of the 398 trials name an investigator with a Belgian affiliation in the registry record, 90 researchers in total. The most active are Copine Sylvie (4), Eva Swinnen (3), Bart Roelands (3), Laurent Simar (3). Industry-sponsored trials rarely name investigators in the registry, so the list mostly reflects academic and hospital-led studies.

How was this analysis made?

AcademicLabs AI read each registry record on its own, with no web search and no facts from model memory, and classified it by disease area, intervention, development stage, sponsor type, Belgian sites and Belgian sponsorship. Counting and every figure were done in code. The trials are registered plans: most are recruiting or not yet open, and none of the figures describe results.

Can I reuse these figures?

Yes. The data and figures are licensed CC BY 4.0: free to reuse with credit “Source: AcademicLabs”, with a link to https://academiclabs.com/research-reports/belgium-clinical-trials-2026.

Can AcademicLabs build a report like this for my field?

Yes. AcademicLabs builds landscapes like this for any country, disease, target or technology, from €1,000 to €10,000 depending on scope, and offers monthly briefings. You can also build them yourself with AcademicLabs.

How to cite. AcademicLabs (2026). Clinical Trials in Belgium 2026. Arne Smolders. https://academiclabs.com/research-reports/belgium-clinical-trials-2026. Data as of 8 October 2026. Licensed CC BY 4.0.

Ask this report

Key figures

Brussels, Leuven and Ghent carry most of the load

Trials per Belgian city

Trials per region

A steady flow of new studies, month after month

New trials by start month, 2026

Cancer leads, but half the trials test no drug at all

Disease area, split by who leads the trial

Development phase

What is being tested

Belgian universities and hospitals lead as many trials as industry

Most active lead sponsors

Belgian-led trials

Half run only in Belgium; the other half connect Belgium to the world

Belgium only or international?

Countries most often sharing a trial with Belgium

Six stories in the data

The obesity-drug race reaches Belgian clinics

Radioactive tracers to treat and to see

An Alzheimer’s blood test at the GP

Antwerp’s tropical institute tests how long protection lasts

Robots in the operating theatre and the training lab

AI and apps enter the trial

Want a report like this for your field?

All 398 trials

How this report was made

Data

AI reads, code counts

Read with care

How to cite

Researchers running the trials

Key questions